Developer docs
API playgroundTry for free, no card

Search company profiles

Gilead Sciences Canada

Full company profile

uuid002dp2g

Namestring
Gilead Sciences Canada
Legal namestring
Gilead Sciences, Inc.
Websiteurl
gilead.ca
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., a publicly-traded biopharmaceutical company listed on NASDAQ under the ticker GILD. The Canadian entity, established in 2006 and headquartered in the Greater Toronto Area (Mississauga/Toronto), commercializes a portfolio of innovative prescription therapies across three core therapeutic areas: Virology (including HIV treatment and prevention, and curative therapies for hepatitis C), Oncology, and Inflammation. The parent company has been operating for more than 35 years with over 17,000 employees globally, and the Canadian operations function as a regional market entity within that enterprise.

The business operates a traditional pharmaceutical go-to-market model: Gilead Sciences Canada generates revenue through one-time prescription product sales, distributing via enterprise field sales to hospitals, clinics, pharmacies, and healthcare provider networks across Canada. Customer-facing activities are organized around healthcare professional communications, disease awareness campaigns, and structured community grants programs spanning HIV, Oncology and Hematology, and Liver disease. The company maintains a Canadian Leadership Team and engages external agency partners (e.g., Ogilvy Health) for creative pharmaceutical marketing, evidenced by a 2026 Cannes Lions Pharma Lions Bronze award.

Pricing is not publicly disclosed and is managed through Canadian healthcare system channels — public formularies, private insurance, and government drug programs. As a regional subsidiary of a large-cap US biopharma, Gilead Sciences Canada benefits from the parent's R&D pipeline, regulatory authorizations, and global commercial infrastructure, while operating within Health Canada's regulatory framework for prescription medicines serving Canadian patients with serious and life-threatening diseases.

Short descriptiontext

Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., commercializing prescription therapies in Virology, Oncology, and Inflammation to Canadian patients through hospitals, pharmacies, and healthcare provider networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HIV antiviral therapies, hepatitis C treatments, oncology therapeutics, biopharmaceutical medicines, inflammatory disease drugs
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Gilead Sciences generates revenue through the sale of prescription pharmaceutical products, including treatments for HIV, hepatitis C, and other serious diseases. The company develops and commercializes innovative medicines globally.

gilead.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gilead Sciences Canada is the Canadian subsidiary of Gilead Sciences, Inc., a biopharmaceutical company that develops, manufactures, and commercializes prescription medicines in three core therapeutic areas: Virology (including HIV treatment and prevention and a cure for hepatitis C), Oncology, and Inflammation. The Canadian entity distributes these therapies through healthcare providers, hospitals, and pharmacies across Canada.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Gilead Sciences Canada is a biopharmaceutical company focused on discovering and delivering transformative therapies for public health challenges. The company operates across three core therapeutic areas: Virology (including HIV treatment and prevention, and hepatitis C), Oncology, and Inflammation. Gilead's portfolio includes HIV treatments and prevention therapies, hepatitis C cures, and investigational therapies for other serious diseases. The company delivers its medicines through community grants programs spanning HIV, Oncology and Hematology, and Liver disease communities, connecting patients with access to care. The company employs more than 17,000 people globally and has been operating for over 35 years.

Product and service4 records
1HIV Treatments and Prevention Therapies
CategoryAntiretroviral / Virology Therapeutics
Description

Prescription pharmaceutical therapies for the treatment and prevention of HIV, developed over 35+ years of innovation; sold to healthcare providers and dispensed through pharmacies and hospitals in Canada.

2Hepatitis C Cure Therapies
CategoryAntiviral / Virology Therapeutics
Description

Prescription curative therapies for hepatitis C, representing a transformative advance in liver disease treatment; distributed through Canadian healthcare providers, hospitals, and pharmacies.

3Oncology Therapies
CategoryOncology Therapeutics
Description

Prescription pharmaceutical therapies for patients impacted by oncological diseases; sold to healthcare providers, hospitals, and specialty oncology centers in Canada.

4Inflammation Therapies
CategoryAnti-inflammatory Therapeutics
Description

Prescription therapies for patients impacted by inflammatory diseases; sold through Canadian healthcare providers and pharmacies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeOthersAnnounced on2026-06-26
Description

Gilead Sciences Canada and Jazz Pharmaceuticals both received Bronze awards at the 2026 Cannes Lions Pharma Lions category, recognizing their respective pharmaceutical creativity campaigns.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Ogilvy Health is the agency partner for Viatris that won a Gold Lion at Cannes Lions 2026. Gilead also participated in the same awards, suggesting agencies are key partners in pharmaceutical marketing campaigns.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian subsidiary of Pfizer Inc., a global biopharmaceutical company. Directly comparable as a major pharma manufacturer/distributor operating across multiple therapeutic areas (oncology, vaccines, inflammation, internal medicine) with enterprise sales into Canadian healthcare providers, hospitals, and pharmacies.

TypeDirect peer
Description

Canadian subsidiary of Novartis AG, a global biopharmaceutical company. Comparable therapeutic area overlap (oncology, inflammation, virology-adjacent) and comparable enterprise sales motion into Canadian healthcare providers.

3AstraZeneca Canada
TypeDirect peer
Description

Canadian subsidiary of AstraZeneca PLC, a major biopharmaceutical company. Comparable across oncology and specialty therapeutics with overlapping enterprise sales motion and similar regulatory/reimbursement exposure in Canada.

TypeDirect peer
Description

Global specialist HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders. The most direct competitor in Gilead's flagship virology franchise, competing head-to-head in HIV treatment and prevention with enterprise sales into the same HCP segments.

TypeDirect peer
Description

Canadian arm of Merck & Co. (MSD), a major biopharmaceutical company. Closely comparable in scale, therapeutic breadth (oncology, vaccines, virology), and enterprise go-to-market motion into Canadian healthcare provider networks.

TypeDirect peer
Description

Canadian operations of F. Hoffmann-La Roche, a global biopharmaceutical leader. Comparable across virology, oncology, and inflammation, with similar enterprise sales motion and specialty-pharma distribution model in Canada.

TypeDirect peer
Description

Canadian pharmaceutical arm of J&J's Innovative Medicine division. Direct peer across virology, oncology, and immunology/inflammation, with comparable enterprise sales infrastructure and specialty-pharma portfolio strategy.

TypeBroad incumbent
Description

Canadian subsidiary of GSK plc, a global biopharmaceutical incumbent. Comparable as a broad-line pharmaceutical company with virology (HIV via ViiV), oncology, and inflammation exposure, though operating across a much wider portfolio than Gilead's focused three therapeutic areas.

9AbbVie Canada
TypeDirect peer
Description

Canadian subsidiary of AbbVie Inc., a global biopharmaceutical firm. Highly comparable given overlapping therapeutic focus on virology (HIV via partnerships), immunology/inflammation, and oncology, with similar specialty-pharma enterprise sales motion in Canada.

10Bristol-Myers Squibb Canada
TypeDirect peer
Description

Canadian subsidiary of Bristol-Myers Squibb, a major biopharmaceutical company. Comparable in oncology and immunology focus, with overlapping virology heritage and similar enterprise sales motion into Canadian hospitals and specialty providers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gilead Sciences Canada

Biopharmaceutical Therapeuticsgilead.ca

Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., commercializing prescription therapies in Virology, Oncology, and Inflammation to Canadian patients through hospitals, pharmacies, and healthcare provider networks.

What Gilead Sciences Canada does

Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., a publicly-traded biopharmaceutical company listed on NASDAQ under the ticker GILD. The Canadian entity, established in 2006 and headquartered in the Greater Toronto Area (Mississauga/Toronto), commercializes a portfolio of innovative prescription therapies across three core therapeutic areas: Virology (including HIV treatment and prevention, and curative therapies for hepatitis C), Oncology, and Inflammation. The parent company has been operating for more than 35 years with over 17,000 employees globally, and the Canadian operations function as a regional market entity within that enterprise.

The business operates a traditional pharmaceutical go-to-market model: Gilead Sciences Canada generates revenue through one-time prescription product sales, distributing via enterprise field sales to hospitals, clinics, pharmacies, and healthcare provider networks across Canada. Customer-facing activities are organized around healthcare professional communications, disease awareness campaigns, and structured community grants programs spanning HIV, Oncology and Hematology, and Liver disease. The company maintains a Canadian Leadership Team and engages external agency partners (e.g., Ogilvy Health) for creative pharmaceutical marketing, evidenced by a 2026 Cannes Lions Pharma Lions Bronze award.

Pricing is not publicly disclosed and is managed through Canadian healthcare system channels — public formularies, private insurance, and government drug programs. As a regional subsidiary of a large-cap US biopharma, Gilead Sciences Canada benefits from the parent's R&D pipeline, regulatory authorizations, and global commercial infrastructure, while operating within Health Canada's regulatory framework for prescription medicines serving Canadian patients with serious and life-threatening diseases.

Gilead Sciences Canada firmographics

Firmographics
Name
Gilead Sciences Canada
Legal name
Gilead Sciences, Inc.
Website
https://gilead.ca
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
251–500 employees
Short description
Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., commercializing prescription therapies in Virology, Oncology, and Inflammation to Canadian patients through hospitals, pharmacies, and healthcare provider networks.
Ownership category
akta.pro rank

Gilead Sciences Canada industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • HIV antiviral therapies
  • Hepatitis C treatments
  • Oncology therapeutics
  • Biopharmaceutical medicines
  • Inflammatory disease drugs

Where Gilead Sciences Canada is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Gilead Sciences Canada business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Gilead Sciences generates revenue through the sale of prescription pharmaceutical products, including treatments for HIV, hepatitis C, and other serious diseases. The company develops and commercializes innovative medicines globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Gilead Sciences Canada product offering

Product offering

Core offering

Gilead Sciences Canada is the Canadian subsidiary of Gilead Sciences, Inc., a biopharmaceutical company that develops, manufactures, and commercializes prescription medicines in three core therapeutic areas: Virology (including HIV treatment and prevention and a cure for hepatitis C), Oncology, and Inflammation. The Canadian entity distributes these therapies through healthcare providers, hospitals, and pharmacies across Canada.

Product overview

Gilead Sciences Canada is a biopharmaceutical company focused on discovering and delivering transformative therapies for public health challenges. The company operates across three core therapeutic areas: Virology (including HIV treatment and prevention, and hepatitis C), Oncology, and Inflammation. Gilead's portfolio includes HIV treatments and prevention therapies, hepatitis C cures, and investigational therapies for other serious diseases. The company delivers its medicines through community grants programs spanning HIV, Oncology and Hematology, and Liver disease communities, connecting patients with access to care. The company employs more than 17,000 people globally and has been operating for over 35 years.

Differentiator

Problem solved

Functional benefit

Products and services

  • HIV Treatments and Prevention Therapies Prescription pharmaceutical therapies for the treatment and prevention of HIV, developed over 35+ years of innovation; sold to healthcare providers and dispensed through pharmacies and hospitals in Canada.
  • Hepatitis C Cure Therapies Prescription curative therapies for hepatitis C, representing a transformative advance in liver disease treatment; distributed through Canadian healthcare providers, hospitals, and pharmacies.
  • Oncology Therapies Prescription pharmaceutical therapies for patients impacted by oncological diseases; sold to healthcare providers, hospitals, and specialty oncology centers in Canada.
  • Inflammation Therapies Prescription therapies for patients impacted by inflammatory diseases; sold through Canadian healthcare providers and pharmacies.

Companies that use Gilead Sciences Canada

Customer profile

Segments1 record

Ideal customer profiles1 record

Gilead Sciences Canada technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gilead Sciences Canada partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Jazz PharmaceuticalsminorOthers · 26 June 2026Gilead Sciences Canada and Jazz Pharmaceuticals both received Bronze awards at the 2026 Cannes Lions Pharma Lions category, recognizing their respective pharmaceutical creativity campaigns.
  • Ogilvy HealthcoreGTM or Marketing PartnerOgilvy Health is the agency partner for Viatris that won a Gold Lion at Cannes Lions 2026. Gilead also participated in the same awards, suggesting agencies are key partners in pharmaceutical marketing campaigns.

Scale indicators3 records

Recent moves3 records

Expansion highlights4 records

Gilead Sciences Canada competitors and assessment

Company assessment

Direct peers

  • Pfizer Canada: Canadian subsidiary of Pfizer Inc., a global biopharmaceutical company. Directly comparable as a major pharma manufacturer/distributor operating across multiple therapeutic areas (oncology, vaccines, inflammation, internal medicine) with enterprise sales into Canadian healthcare providers, hospitals, and pharmacies.
  • Novartis Pharmaceuticals Canada: Canadian subsidiary of Novartis AG, a global biopharmaceutical company. Comparable therapeutic area overlap (oncology, inflammation, virology-adjacent) and comparable enterprise sales motion into Canadian healthcare providers.
  • AstraZeneca Canada: Canadian subsidiary of AstraZeneca PLC, a major biopharmaceutical company. Comparable across oncology and specialty therapeutics with overlapping enterprise sales motion and similar regulatory/reimbursement exposure in Canada.
  • ViiV Healthcare: Global specialist HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders. The most direct competitor in Gilead's flagship virology franchise, competing head-to-head in HIV treatment and prevention with enterprise sales into the same HCP segments.
  • Merck Canada: Canadian arm of Merck & Co. (MSD), a major biopharmaceutical company. Closely comparable in scale, therapeutic breadth (oncology, vaccines, virology), and enterprise go-to-market motion into Canadian healthcare provider networks.
  • Roche Canada: Canadian operations of F. Hoffmann-La Roche, a global biopharmaceutical leader. Comparable across virology, oncology, and inflammation, with similar enterprise sales motion and specialty-pharma distribution model in Canada.
  • Johnson & Johnson Innovative Medicine Canada (Janssen): Canadian pharmaceutical arm of J&J's Innovative Medicine division. Direct peer across virology, oncology, and immunology/inflammation, with comparable enterprise sales infrastructure and specialty-pharma portfolio strategy.
  • AbbVie Canada: Canadian subsidiary of AbbVie Inc., a global biopharmaceutical firm. Highly comparable given overlapping therapeutic focus on virology (HIV via partnerships), immunology/inflammation, and oncology, with similar specialty-pharma enterprise sales motion in Canada.
  • Bristol-Myers Squibb Canada: Canadian subsidiary of Bristol-Myers Squibb, a major biopharmaceutical company. Comparable in oncology and immunology focus, with overlapping virology heritage and similar enterprise sales motion into Canadian hospitals and specialty providers.

Broad incumbents

  • GSK Canada: Canadian subsidiary of GSK plc, a global biopharmaceutical incumbent. Comparable as a broad-line pharmaceutical company with virology (HIV via ViiV), oncology, and inflammation exposure, though operating across a much wider portfolio than Gilead's focused three therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Gilead Sciences Canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gilead Sciences Canada leadership team

Management profile

Number of profiles

Gilead Sciences Canada subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Gilead Sciences Canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gilead Sciences Canada M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gilead Sciences Canada

What does Gilead Sciences Canada do?

Gilead Sciences Canada is the Canadian subsidiary of Gilead Sciences, Inc., a biopharmaceutical company that develops, manufactures, and commercializes prescription medicines in three core therapeutic areas: Virology (including HIV treatment and prevention and a cure for hepatitis C), Oncology, and Inflammation. The Canadian entity distributes these therapies through healthcare providers, hospitals, and pharmacies across Canada.

Is Gilead Sciences Canada a public or private company?

Gilead Sciences Canada is a public company. It is classified as public and is currently operating.

When was Gilead Sciences Canada founded?

Gilead Sciences Canada was founded in 1987. It employs 251 to 500 people.

Where is Gilead Sciences Canada based?

Gilead Sciences Canada is headquartered in Mississauga, Canada, in the North America region.

How does Gilead Sciences Canada make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Gilead Sciences Canada's main competitors?

Direct peers on record are Pfizer Canada, Novartis Pharmaceuticals Canada, AstraZeneca Canada, ViiV Healthcare, Merck Canada, Roche Canada, Johnson & Johnson Innovative Medicine Canada (Janssen), AbbVie Canada and Bristol-Myers Squibb Canada. GSK Canada is listed as a broad incumbent.

Does Gilead Sciences Canada have an API?

No public API is recorded for Gilead Sciences Canada.

What industry is Gilead Sciences Canada in?

Gilead Sciences Canada's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FiercePharmaOtters, bears and Pharma Lions: inside Gilead’s bronze-winning Cannes spotGilead Sciences, through its Canadian affiliate Gilead Canada, won a bronze Lion at the Cannes Lions Festival of Creativity for its "Animal Attraction" Descovy advertisement, created with Toronto-based agency The Local Collective. The campaign uses AI-generated animals—a bear and otter, which are slang terms within the HIV community—to promote the HIV prevention and treatment drug in a culturally specific, humorous way, targeting informed patients rather than explaining the disease to them. The award highlights Gilead's evolving approach to HIV drug marketing and the broader trend of pharmaceutical companies gaining recognition for creative advertising that balances regulatory constraints with cultural relevance.FiercePharmaPharma’s Cannes-do attitude sees industry return to triumphNovartis won the Grand Prix at the 2026 Cannes Lions Festival for its Super Bowl ad 'Relax Your Tight End,' a prostate cancer screening campaign that blended sports, celebrity, and patient stories to address screening anxiety, marking a major return for Big Pharma at the awards after years of medical technology dominance. Viatris also secured Gold for its 'Make Love Last' campaign with agency Ogilvy Health, while Gilead Sciences Canada and Jazz Pharmaceuticals received Bronze awards, as new AI integrity rules contributed to a drop in total entries from nearly 27,000 in 2025 to 20,050. The awards underscore a post-pandemic shift back toward pharma companies leveraging culturally resonant, celebrity-driven campaigns to achieve both creative recognition and measurable health behavior change.RoastbriefCannes Lions 2026 unveils the Pharma Lions shortlist, featuring 23 finalists that show how pharmaceutical creativity is connecting science, innovation, patients and healthcare professionalsCannes Lions 2026 has released the Pharma Lions shortlist featuring 23 finalists across categories including branded promotion, unbranded awareness, and patient engagement. Major pharmaceutical companies shortlisted include Viatris, AstraZeneca, Novartis, Bayer, Gilead Sciences, and Genentech, with creative work from agencies such as Ogilvy, VML, and Area 23. The geographic spread spans the United States, Canada, United Kingdom, Mainland China, Spain, Taiwan, Switzerland, India, and the Netherlands, reflecting the global growth of pharmaceutical creativity as a regulated yet innovative communications discipline.BioSpaceLYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITISHealth Canada has approved Gilead Sciences' LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare autoimmune liver disease affecting approximately 13,000 Canadians. The Phase 3 RESPONSE trial demonstrated that 62% of LYVDELZI-treated patients achieved biochemical response at 12 months versus 20% on placebo, making it the only medicine to show statistically significant improvements in both pruritus and cholestasis markers. The approval is conditional, pending results from confirmatory clinical trials Gilead must conduct within an established timeframe.BioXconomyAI’s impact on pharma and compliance functionsThe article discusses how AI is transforming legal and compliance functions within the pharmaceutical industry, highlighting its applications in contract management, risk detection, and drug development. Jessica Laham from Gilead Sciences Canada emphasizes the importance of balancing innovation with ethics and regulatory compliance while mitigating AI-related risks.The Times of IndiaLenacapavir HIV shot approved in US may enter Canada by 2026; just two injections needed a year - The Economic TimesGilead Sciences' lenacapavir, a twice-yearly injectable HIV prevention drug, received US FDA approval and is under review by Health Canada, with potential availability in Canada by mid-2026. Clinical trials demonstrated near-total effectiveness, including zero new infections among over 2,000 high-risk women in Africa and only two infections among gay and bisexual men and transgender women. However, concerns have emerged over its high US list price of $28,218 per year and potential access barriers for marginalized groups.